Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Sells 250,804 Shares of Company Stock

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report) major shareholder Jorey Chernett sold 250,804 shares of the stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $2.39, for a total value of $599,421.56. Following the transaction, the insider owned 10,370,184 shares in the company, valued at $24,784,739.76. This trade represents a 2.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

  • On Friday, November 13th, Jorey Chernett sold 2,187,051 shares of Neuronetics stock. The stock was sold at an average price of $1.15, for a total value of $2,515,108.65.
  • On Thursday, November 12th, Jorey Chernett sold 706,840 shares of Neuronetics stock. The stock was sold at an average price of $1.43, for a total value of $1,010,781.20.
  • On Wednesday, November 11th, Jorey Chernett sold 86,757 shares of Neuronetics stock. The stock was sold at an average price of $1.61, for a total value of $139,678.77.
  • On Monday, November 9th, Jorey Chernett sold 103,959 shares of Neuronetics stock. The stock was sold at an average price of $2.06, for a total value of $214,155.54.
  • On Monday, November 9th, Jorey Chernett purchased 40,000 shares of Neuronetics stock. The shares were acquired at an average price of $1.99 per share, for a total transaction of $79,600.00.
  • On Friday, October 30th, Jorey Chernett purchased 18,000 shares of Neuronetics stock. The shares were acquired at an average cost of $2.27 per share, for a total transaction of $40,860.00.

Neuronetics Price Performance

Shares of STIM stock traded down $0.04 during trading hours on Friday, hitting $1.39. 16,248,659 shares of the company’s stock were exchanged, compared to its average volume of 2,081,244. The company has a market capitalization of $108.04 million, a PE ratio of -4.21 and a beta of 1.36. The company has a current ratio of 2.01, a quick ratio of 1.82 and a debt-to-equity ratio of 2.76. Neuronetics, Inc. has a 12-month low of $0.80 and a 12-month high of $3.44. The business’s 50 day simple moving average is $2.35 and its 200-day simple moving average is $1.87.

Neuronetics (NASDAQ:STIM – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.07. Neuronetics had a negative net margin of 14.45% and a negative return on equity of 102.23%. The company had revenue of $41.96 million during the quarter, compared to analysts’ expectations of $40.42 million. On average, equities research analysts anticipate that Neuronetics, Inc. will post -0.30 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STIM. Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a research note on Tuesday, July 21st. B. Riley Financial boosted their target price on Neuronetics from $5.00 to $6.00 and gave the company a “buy” rating in a research note on Friday, November 6th. BTIG Research reissued a “buy” rating and issued a $6.00 target price on shares of Neuronetics in a research note on Thursday, September 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a report on Monday, September 14th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.00.

Get Our Latest Report on STIM

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Jump Financial LLC bought a new stake in Neuronetics during the 3rd quarter valued at $69,000. Marshall Wace LLP boosted its position in Neuronetics by 219.5% during the 3rd quarter. Marshall Wace LLP now owns 1,551,840 shares of the company’s stock valued at $3,631,000 after buying an additional 1,066,148 shares during the period. Empowered Funds LLC purchased a new stake in Neuronetics during the 3rd quarter valued at $211,000. HighTower Advisors LLC grew its holdings in Neuronetics by 95.4% in the 3rd quarter. HighTower Advisors LLC now owns 1,101,502 shares of the company’s stock worth $2,578,000 after acquiring an additional 537,761 shares during the last quarter. Finally, Jefferies Financial Group Inc. bought a new stake in Neuronetics in the 3rd quarter worth $176,000. 53.59% of the stock is owned by hedge funds and other institutional investors.

Latest Neuronetics News

Investors following STIM have been watching these news items:

  • Positive Sentiment: Third-quarter revenue was $41.96 million, above the $40.43 million analyst estimate, while its $0.02-per-share loss was narrower than the expected $0.09 loss. The results may support sentiment about improving performance. Article: Neuronetics stock: Q3 revenue rises as loss narrows
  • Negative Sentiment: Major shareholder Jorey Chernett disclosed several sales from November 6–13, totaling about 3.34 million shares, partly offset by a 40,000-share purchase. After the latest sale, Chernett held about 7.33 million shares. The scale of the selling may raise concerns about near-term supply and investor confidence. SEC filing on Chernett’s transactions

About Neuronetics

(Get Free Report)

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.

Read More

Insider Buying and Selling by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.